AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25924668 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care prior to intervention implementation)
Number of subjects: 94000
Study 22773282 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid supplementation (0.14 mg lutein + 0.0006 mg zeaxanthin)
Number of subjects: 229
Study 22773282 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% glucose solution)
Number of subjects: 229
Study 21358498 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom laminated mouthguard with normal palatal surface
Number of subjects: 27
Study 21358498 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom laminated mouthguard with palatal coverage up to the gingival margin
Number of subjects: 27
Study 21358498 — intervention group
Group type: COMPARATOR
Intervention: No mouthguard
Number of subjects: 27
Study 18165564 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (6 microg x kg(‐1) x h(‐1) for 10 min followed by 0.2 microg x kg(‐1) x h(‐1))
Number of subjects: 46
Study 18165564 — intervention group
Group type: COMPARATOR
Intervention: Propofol (6 mg x kg(‐1) x h(‐1) for 10 min followed by 2.4 mg x kg(‐1) x h(‐1))
Number of subjects: 46
Study 17065944 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ankle-foot orthoses (DAFOs)
Number of subjects: 23
Study 17065944 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study 14872504 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg once daily
Number of subjects: 189
Study 14872504 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg three times daily
Number of subjects: 189
Study 10989243 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroPlant‐LNG intrauterine system (IUS) delivering approximately 10 microg per day of LNG
Number of subjects: 30
Study 10989243 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroPlant‐LNG intrauterine system (IUS) delivering approximately 14 microg per day of LNG
Number of subjects: 30
Study 10989243 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroPlant‐LNG intrauterine system (IUS)
Number of subjects: 30
Study 9072985 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional water-based paint
Number of subjects: 17
Study 9072985 — intervention group
Group type: COMPARATOR
Intervention: VOC-free paint
Number of subjects: 17
Study 9072985 — intervention group
Group type: EXPERIMENTAL
Intervention: Both paints
Number of subjects: 17
Study 8339215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, 5-fluorouracil, and prednisone with tamoxifen
Number of subjects: 564
Study 8339215 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, 5-fluorouracil, and prednisone without tamoxifen
Number of subjects: 564
Study 3537245 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (single dose)
Number of subjects: 16
Study 3537245 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (6-10 day course)
Number of subjects: 16
Study 3537245 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (long-term therapy)
Number of subjects: 16
Study 3537245 — intervention group
Group type: COMPARATOR
Intervention: Control (7-day control period)
Number of subjects: 16
Study 29905619 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF capsule
Number of subjects: 0
Study 29905619 — intervention group
Group type: COMPARATOR
Intervention: MMF dispersible tablet
Number of subjects: 0
Study 29905619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 0
Study 27637335 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) - 0.092 g EPA+DHA/kg body weight/day
Number of subjects: 60
Study 27637335 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care only (Control)
Number of subjects: 60
Study 27637335 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 60
Study 24378525 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) plus membrane filtration (MF)
Number of subjects: 14
Study 24378525 — intervention group
Group type: COMPARATOR
Intervention: Immunoadsorption (IA) alone
Number of subjects: 14
Study 23043944 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day CIDR protocol
Number of subjects: 543
Study 23043944 — intervention group
Group type: COMPARATOR
Intervention: 5-day CIDR protocol
Number of subjects: 543
Study 23043944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexed semen
Number of subjects: 543
Study 21079403 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal pouch interposition (PO group)
Number of subjects: 38
Study 21079403 — intervention group
Group type: COMPARATOR
Intervention: Jejunal interposition (IP group)
Number of subjects: 38
Study 18551124 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin users (88 participants, 54% of total)
Number of subjects: 163
Study 18551124 — intervention group
Group type: COMPARATOR
Intervention: Noninsulin users (75 participants, 46% of total)
Number of subjects: 163
Study 18551124 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin users (after adjustment)
Number of subjects: 163
Study 18551124 — intervention group
Group type: COMPARATOR
Intervention: Noninsulin users (after adjustment)
Number of subjects: 163
Study 15838684 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of ultrasonic scaler and Periopolisher diamond‐coated inserts (US‐POL)
Number of subjects: 40
Study 15838684 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand instruments (MANUAL)
Number of subjects: 40
Study 15838684 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioplaner-Periopolisher system (PPL-POL)
Number of subjects: 40
Study 15838684 — intervention group
Group type: EXPERIMENTAL
Intervention: Periokit ultrasonic-designed scalers (PERIOKIT)
Number of subjects: 40
Study 15838684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler alone
Number of subjects: 40
Study 15838684 — intervention group
Group type: COMPARATOR
Intervention: Hand instruments
Number of subjects: 40
Study 12431033 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning and recalling animal tracks
Number of subjects: 0
Study 12431033 — intervention group
Group type: COMPARATOR
Intervention: Learning and recalling kitchen implements
Number of subjects: 0
Study 10353514 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV‐TV vaccine
Number of subjects: 2398
Study 10353514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2398
Study 8626881 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg immediate-release (IR) verapamil every 8 hours
Number of subjects: 11
Study 8626881 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg controlled-release (CR) formulation once daily
Number of subjects: 11
Study 8626881 — intervention group
Group type: COMPARATOR
Intervention: Both formulations (IR and CR)
Number of subjects: 11
Study 2123907 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue-type plasminogen activator (rt-PA) (Group A)
Number of subjects: 34
Study 2123907 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue-type plasminogen activator (rt-PA) (Group B)
Number of subjects: 34
Study 2123907 — intervention group
Group type: COMPARATOR
Intervention: conventional therapy (Group C)
Number of subjects: 34
Study 2123907 — intervention group
Group type: COMPARATOR
Intervention: Group C (conventional therapy)
Number of subjects: 34
Study 2123907 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (rt-PA)
Number of subjects: 34
Study 2123907 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (rt-PA)
Number of subjects: 34
Study 6994665 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate at 10 mg/kg body weight for three days
Number of subjects: 34
Study 6994665 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate at 10 mg/kg body weight for six days
Number of subjects: 34
Study 29691983 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoding intervention (15 × 20-min sessions)
Number of subjects: 8
Study 29691983 — intervention group
Group type: COMPARATOR
Intervention: Language intervention (control)
Number of subjects: 8
Study 28948706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow-derived mononuclear cells (BM-MNCs) 2-8 days after successful reperfusion for AMI added on top of optimal standard of care.
Number of subjects: 3000
Study 28948706 — intervention group
Group type: COMPARATOR
Intervention: Optimal standard of care.
Number of subjects: 3000
Study 26525049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 10
Study 26525049 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 23453612 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine pre‐procedure rinse
Number of subjects: 0
Study 23453612 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g amoxicillin antibiotic prophylaxis
Number of subjects: 0
Study 23453612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21494037 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Number of subjects: 80
Study 21494037 — intervention group
Group type: COMPARATOR
Intervention: Conventional polypectomy
Number of subjects: 80
Study 19781270 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose steroid combined with two-dose daclizumab and tacrolimus
Number of subjects: 67
Study 19781270 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol (steroid withdrawn after 3 months)
Number of subjects: 67
Study 16860496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibroacoustic stimulation (3-s stimulus with an artificial larynx)
Number of subjects: 2833
Study 16860496 — intervention group
Group type: COMPARATOR
Intervention: Observation time extended for 60 min (Control group B)
Number of subjects: 2833
Study 15515112 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 928
Study 15515112 — intervention group
Group type: COMPARATOR
Intervention: Open mesh repair
Number of subjects: 928
Study 11678788 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 0
Study 11678788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9140670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (0.05 mg intracoronary during procedure, followed by 20 mg/day orally for 6 months)
Number of subjects: 36
Study 9140670 — intervention group
Group type: COMPARATOR
Intervention: Nitrates (0.8 mg intracoronary during procedure, followed by 80-120 mg/day orally for 6 months)
Number of subjects: 36
Study 7526025 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic membranes used during hemodialysis
Number of subjects: 0
Study 7526025 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic concentrations of the platelet specific agonist ADP
Number of subjects: 0
Study 7526025 — intervention group
Group type: COMPARATOR
Intervention: Complement factors C3a or C5a
Number of subjects: 0
Study 2889217 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine twice daily
Number of subjects: 65
Study 2889217 — intervention group
Group type: COMPARATOR
Intervention: 2 mg dexchlorpheniramine maleate 3-times daily
Number of subjects: 65
Study 2792117 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory video film (14 min)
Number of subjects: 65
Study 2792117 — intervention group
Group type: COMPARATOR
Intervention: No video film (Control Group 1)
Number of subjects: 65
Study 4686554 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aerosols of prostaglandin F(2)alpha (PGF(2)alpha)
Number of subjects: 20
Study 4686554 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aerosols of histamine
Number of subjects: 20
Study 4686554 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aerosols of prostaglandin E(2) (PGE(2))
Number of subjects: 20
Study 4686554 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous inhalation of a 100-times higher PGE(2) dose with PGF(2)alpha
Number of subjects: 20
Study 31488494 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral azithromycin (20 mg/kg)
Number of subjects: 21712
Study 31488494 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 21712
Study 29657696 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention (MBRP)
Number of subjects: 60
Study 29657696 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 60
Study 25798729 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 847
Study 25798729 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 847
Study 23559676 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 33
Study 23559676 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (without GH)
Number of subjects: 33
Study 21733178 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0
Study 21733178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study 21733178 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with fentanyl
Number of subjects: 0
Study 21733178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function tests (Short Memory Orientation Memory Concentration Test and Rancho Los Amigos Scale)
Number of subjects: 0
Study 18850309 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% alanine (ALA)
Number of subjects: 10
Study 18850309 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% alanine and 6% sucrose (ALA-CHO)
Number of subjects: 10
Study 18850309 — intervention group
Group type: COMPARATOR
Intervention: 6% sucrose (CHO)
Number of subjects: 10
Study 18850309 — intervention group
Group type: COMPARATOR
Intervention: artificially sweetened placebo (PLC)
Number of subjects: 10
Study 16914701 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (6 mg/kg daily)
Number of subjects: 246
Study 16914701 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (initial low-dose gentamicin plus either an antistaphylococcal penicillin or vancomycin)
Number of subjects: 246
Study 16914701 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 246
Study 16914701 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 246
Study 14992900 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/h infusion)
Number of subjects: 100
Study 14992900 — intervention group
Group type: COMPARATOR
Intervention: Heparin (150 to 300 U/kg bolus) with protamine reversal
Number of subjects: 100
Study 14992900 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 100
Study 14992900 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 100
Study 11382659 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg/d)
Number of subjects: 50
Study 9427886 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese pediatric subjects at diagnosis
Number of subjects: 0
Study 9427886 — intervention group
Group type: COMPARATOR
Intervention: Anorexia nervosa patients at diagnosis
Number of subjects: 0
Study 9427886 — intervention group
Group type: COMPARATOR
Intervention: Bulimia nervosa patients at diagnosis
Number of subjects: 0
Study 9427886 — intervention group
Group type: COMPARATOR
Intervention: Healthy boys and girls at various Tanner stages
Number of subjects: 0
Study 8489977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine
Number of subjects: 60
Study 8489977 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine alone (Control)
Number of subjects: 60
Study 3693714 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing process approach
Number of subjects: 0
Study 3693714 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study 31067214 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical medication review (CMR)
Number of subjects: 629
Study 31067214 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 629
Study 28882471 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP)
Number of subjects: 259
Study 28882471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 26133666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 37
Study 26133666 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ER niacin)
Number of subjects: 37
Study 26133666 — intervention group
Group type: COMPARATOR
Intervention: Control HDL
Number of subjects: 37
Study 23205593 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Cognitive Behavioural Therapy (SCBT)
Number of subjects: 57
Study 23205593 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive Behaviour Therapy (ECBT)
Number of subjects: 57
Study 23205593 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 57
Study 21980168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg MDMA
Number of subjects: 10
Study 21980168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg/kg MDMA
Number of subjects: 10
Study 18697901 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K supplementation (500 microg/day phylloquinone)
Number of subjects: 355
Study 18697901 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin K supplementation)
Number of subjects: 355
Study 15972298 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine 2 mg/kg/day
Number of subjects: 72
Study 15972298 — intervention group
Group type: COMPARATOR
Intervention: 5-aminosalicylic acid 3.2 g/day
Number of subjects: 72
Study 12947422 — intervention group
Group type: COMPARATOR
Intervention: Ordinary caviar paste (25 g daily for 3 weeks)
Number of subjects: 16
Study 12947422 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil enriched caviar paste (25 g daily for 3 weeks)
Number of subjects: 16
Study 11930370 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-bonded bridges with grooves in abutment teeth preparation
Number of subjects: 0
Study 11930370 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-bonded bridges placed in the maxilla
Number of subjects: 0
Study 11930370 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonding systems (etching/Clearfil F2, sand blasting/Panavia EX, silica-coating/Microfill Pontic C)
Number of subjects: 0
Study 11930370 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica coating/Microfill Pontic C in rebonded bridges
Number of subjects: 0
Study 8954425 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate wound dressing
Number of subjects: 92
Study 8954425 — intervention group
Group type: COMPARATOR
Intervention: Dextranomer paste (Control)
Number of subjects: 92
Study 1722576 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal CVS
Number of subjects: 2931
Study 1722576 — intervention group
Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 2931
Study 1722576 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical CVS
Number of subjects: 2931
Study 6130952 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg etintidine
Number of subjects: 5
Study 6130952 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg cimetidine
Number of subjects: 5
Study 6130952 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg etintidine
Number of subjects: 5
Study 6130952 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg cimetidine
Number of subjects: 5
Study 6130952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 29684829 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme (n=81)
Number of subjects: 146
Study 29684829 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (n=65)
Number of subjects: 146
Study 27487406 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory Biofield Therapy (OBFT)
Number of subjects: 30
Study 27487406 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 24717640 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg, orally once a day for 6 months)
Number of subjects: 60
Study 24717640 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally once a day for 6 months)
Number of subjects: 60
Study 24717640 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 60
Study 24717640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22908774 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg administered without cost for 4 months (Group A)
Number of subjects: 70
Study 22908774 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5 mg administered with cost for 4 months (Group B)
Number of subjects: 70
Study 22908774 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg administered without cost (Group A)
Number of subjects: 70
Study 22908774 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5 mg administered with cost (Group B)
Number of subjects: 70
Study 20149716 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfilcon A Plus
Number of subjects: 0
Study 20149716 — intervention group
Group type: EXPERIMENTAL
Intervention: Other lenses (Hilafilcon B, Etafilcon A Plus, Nelfilcon A)
Number of subjects: 0
Study 20149716 — intervention group
Group type: EXPERIMENTAL
Intervention: All lenses
Number of subjects: 0
Study 18333867 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral (14)C‐labelled maraviroc
Number of subjects: 20
Study 18333867 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg intravenous maraviroc
Number of subjects: 20
Study 18333867 — intervention group
Group type: COMPARATOR
Intervention: 100 mg oral maraviroc
Number of subjects: 20
Study 15819354 — intervention group
Group type: EXPERIMENTAL
Intervention: Test gel containing ACP
Number of subjects: 0
Study 15819354 — intervention group
Group type: COMPARATOR
Intervention: Control gel
Number of subjects: 0
Study 12464983 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (titrated up to 40 mg daily)
Number of subjects: 2204
Study 12464983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2204
Study 9475259 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (QUI)
Number of subjects: 44
Study 9475259 — intervention group
Group type: COMPARATOR
Intervention: Triamterene/Hydrochlorothiazide (THCT)
Number of subjects: 44